Idursulfase Solution Articles
Shire’s fourth-quarter 2009 earnings significantly beat expectations
22 February 2010
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
2 November 2009
Shire sales up 20% pre-Adderall demise
1 May 2009
Shire's HGT unveils ambitious growth plan, doubling sales contribution to 30% by 2015
1 December 2008
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
10 November 2008
Shire
2 June 2008
Shire's Elaprase cleared in Mexico
18 February 2008
Shire posts "best ever" results
12 November 2007
Japan's MHLW OKs Shire's Elaprase
15 October 2007
Canada OKs Elaprase for Hunter syndrome
25 June 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
Shire's 2006 income hits $278M, sales up 16%
26 February 2007
Shire's Elaprase gets EU OK for Hunter synd
22 January 2007
Shire's Elaprase gets EU OK for Hunter synd
22 January 2007
Shire's 3rd-qtr 2006 revenue rises 19%
6 November 2006
Shire's Elaprase gets nod from EMEA's CHMP
30 October 2006
Industry bodies oppose annual revision of Japan
7 August 2006
Stock Commentary - Europe - week to Aug 7, 2006
7 August 2006
Shire's Elaprase cleared by US regulators
26 July 2006
FDA extends review period for Shire's Elaprase
22 May 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
Shire submits BLA for Elaprase in MPS
5 December 2005
Showing 1-28 of 28 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
